| Norton Healthcare

A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK – RDOTAP/HPV-16 E6 & E7 Peptides) and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy as a First Line Treatment in Subjects with Recurrent and/or Metastatic Head and Neck Cancer and Hig

Sub-indication: Head and Neck Cancer

Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: PDS Biotechnology Corporation

Learn more at ClinicalTrials.gov

Email for more information: Head&Neck-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.